Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Edwards Lifesciences Reports Fourth Quarter Results
February 2, 2017 12:50 PM EST
Northland Capital Markets analyst Suraj Kalia is sticking with her Outperform rating and $105 price target on Edwards Lifesciences (NYSE: EW) even though the company is hard time meeting lofty Street expectations.
Kalia commented, "Q4-16 revs @ $768M > consensus @ $758M & our estimate @ $763M. GAAP EPS @ $0.73 > our estimate @ $0.71 &... More
February 2, 2017 9:34 AM EST
Leerink Partners downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $98.02 yesterday.
...
More
February 1, 2017 4:17 PM EST
Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.75, $0.03 better than the analyst estimate of $0.72. Revenue for the quarter came in at $767.7 million versus the consensus estimate of $759.54 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2017 EPS of $0.79-$0.89, versus the consensus of $0.81.... More
